's Chart of the Day - Genomic Health
Related Stocks
 GHDX - Genomic Health Inc

The Barchart Chart of the Day belongs to the biomedical company Genomic Health (GHDX). I found the stock by using Barchart to sort today's Top Stocks to Own list first by the highest Weighted Alpha, then I used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 8/6 the stock gained 24.72%.

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.


Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • 131.53+ Weighted Alpha
  • 128.66% gain in the last year
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 14 new highs and up 22.83% in the last month
  • Relative Strength Index 80.63%
  • Technical support level at 68.20
  • Recently traded at 70.84 with a 50 day moving average of 58.89

Fundamental factors:

  • Market Cap $2.48 billion
  • P/E 136.84
  • Revenue expected to grow 12.00% this year and another 10.50% next year
  • Earnings estimated to increase 5200.00% this year, an additional 58.50% next year and continue to compound at an annual rate of 361.10% for the next 5 years
  • Wall Street analysts issued 3 strong buy, 7 hold and 2 under perform recommendations on the stock